Selected NSCLC patients had 11-month PFS after local treatment for durvalumab oligoprogression

In 41 selected patients with oligoprogressive NSCLC after chemoradiotherapy and durvalumab, local ablative treatment alone was followed by 11-month median PFS.

KEY POINTS

  • This multicenter retrospective study included patients with unresectable stage IIB–III non-small cell lung cancer who developed progression after definitive chemoradiotherapy and at least one dose of consolidation durvalumab between 2016 and 2023. Across seven centers in Italy, the United States, and the Netherlands, 198 patients with progression were identified, of whom 41 received exclusive local ablative therapy (LAT) for oligoprogression and formed the primary study cohort. Another 15 received palliative-intent local treatment and were analyzed descriptively.
  • Oligoprogression was defined as ≤5 progressing lesions across ≤3 organs, with all progressive sites treated using radical-intent radiotherapy, surgery, or cryoablation. LAT consisted of radiotherapy in 29/41 patients (71%), surgery with or without RT in 11 (27%), and cryoablation in one (2%). Radical radiation schedules included approximately 48–60 Gy in 1.8–2 Gy fractions for mediastinal nodes and SBRT regimens such as 16–27 Gy in one to three fractions for other sites. No additional systemic treatment was initiated at the first progression treated with LAT.
  • Brain involvement was common despite limited overall progression. Among LAT-treated patients, 56% had brain metastases, including 44% with isolated brain progression. Thoracic-only progression occurred in 29%, while 46% had completed the planned 12 months of durvalumab. At progression, 78% had ECOG performance status 0–1, reflecting a selected population considered suitable for aggressive local treatment.
  • Median progression-free survival from LAT was 11.0 months (95% CI 7.9–36.7), with one- and two-year PFS rates of 47.2% and 32.6%, respectively. Median overall survival was 18.7 months (95% CI 11.1–not reached), with one- and two-year OS rates of 61.7% and 46.1%. Median follow-up was 27.8 months. These outcomes describe patients selected for LAT and cannot be interpreted as treatment effects without an appropriate comparator.
  • Longer disease control during durvalumab was independently associated with better outcomes after LAT. A progression-free interval of ≥12 months from durvalumab initiation was associated with improved OS (adjusted HR 0.33, 95% CI 0.12–0.86; p=0.023) and PFS (adjusted HR 0.39, 95% CI 0.17–0.87; p=0.022). Median PFS after LAT was 17.4 versus 8.7 months in patients with longer versus shorter prior durvalumab disease control, while median OS was not reached versus 10.4 months (p=0.014).
  • Absence of brain progression was another independent favorable prognostic factor. Patients without brain involvement had lower adjusted hazards of death (HR 0.30, 95% CI 0.11–0.87; p=0.026) and progression or death (HR 0.43, 95% CI 0.19–0.99; p=0.049). Median OS was 9.1 months with brain involvement versus not reached without brain involvement (p=0.014). In contrast, PD-L1 expression, histology, and local treatment modality were not significantly associated with OS in exploratory analyses.
  • The study does not demonstrate that LAT is superior to systemic therapy. The 15-patient palliative-treatment cohort had median PFS and OS of 2.6 and 4.8 months, respectively, but was not a matched control group and included fewer patients with favorable performance status. Patients receiving systemic treatment at progression were excluded from the primary analysis, treatment selection was nonrandomized, and no standardized comparative toxicity or quality-of-life assessment established the benefits or risks of deferring systemic therapy.

CLINICAL TAKEAWAY

Exclusive local ablative treatment may offer a period of disease control without immediate additional systemic therapy in carefully selected patients with oligoprogressive NSCLC after chemoradiotherapy and durvalumab. A longer preceding response to durvalumab and absence of brain progression were associated with better outcomes, but prospective comparative studies are needed before LAT alone can be recommended as a preferred salvage strategy.

SOURCE

European Journal of Cancer

Browse more research Suggest a correction